|
Parkinson Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
In addition, those pathological neurofilament accumulations are known in α-synuclein in Parkinson's disease (PD), Aβ and tau in Alzheimer's disease (AD), polyglutamine in CAG trinucleotide repeat disorders, superoxide dismutase 1 (SOD1), TAR DNA-binding protein 43 (TDP43), neuronal FUS proteins, optineurin (OPTN), ubiquilin 2 (UBQLN2), and dipeptide repeat protein (DRP) in amyotrophic lateral sclerosis (ALS).
|
31820696 |
2020 |
|
Parkinson Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
Previously, we engineered potentiated Hsp104 variants to suppress the proteotoxicity, aggregation, and mislocalization of FUS and other proteins that aggregate in ALS/FTD and Parkinson's disease.
|
31171724 |
2019 |
|
Parkinson Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
We also examined the bioavailability and behavioral improvement in a 6-hydroxydopamine-lesioned rat model of PD following 2 weeks' FUS-liposomal combinatorial treatment.
|
30043675 |
2018 |
|
Parkinson Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
A prominent feature of both ALS and PD is the accumulation of protein inclusions in the cytoplasm of degenerating neurons; however, the particular proteins constituting these inclusions vary: the RNA-binding proteins TDP-43 and FUS are most notable in ALS, while α-synuclein aggregates into Lewy bodies in PD.
|
29243911 |
2018 |
|
Parkinson Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
After only a single treatment, our strategy led to therapeutically relevant levels of GDNF protein content in the FUS-targeted regions in the striatum of the 6-OHDA-induced rat model of PD, which lasted at least up to 10 weeks.
|
28511006 |
2017 |
|
Parkinson Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
Fused-In-Sarcoma (FUS) is a candidate gene for neurological disorders including motor neurone disease and Parkinson׳s disease in addition to various types of cancer.
|
25451114 |
2015 |
|
Parkinson Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
We investigated the contribution of rare variants in seven genes of known relevance to dementias (β-amyloid precursor protein (APP), PSEN1/2, MAPT (microtubule-associated protein tau), fused in sarcoma (FUS), granulin (GRN) and TAR DNA-binding protein 43 (TDP-43)) to PD and PD plus dementia (PD+D) in a discovery sample of 376 individuals with PD and followed by the genotyping of 25 out of the 27 identified variants with a minor allele frequency <5% in 975 individuals with PD, 93 cases with Lewy body disease on neuropathological examination, 613 individuals with Alzheimer's disease (AD), 182 cases with frontotemporal dementia and 1014 general population controls.
|
25604855 |
2015 |
|
Parkinson Disease
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
These findings and previous studies have shown that variants within the FUS gene are not a common cause of PD or ET, in comparison to their role in ALS.
|
24262168 |
2014 |
|
Parkinson Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
The FUS gene is not a genetic risk factor for PD in the population of Chinese Han ethnicity.
|
24080306 |
2014 |